Sandoz’s Keren Haruvi named chair of AAM’s board of directors
The board of directors of the Association for Accessible Medicines has named as its new chairperson, Keren Haruvi, president of Sandoz North America, who was elected for a one-year term.
“I am honored and excited about the opportunity to be the Association for Accessible Medicines board of directors chair in 2024,” said Haruvi. “During my tenure, my focus will be working with key stakeholders to promote predictable and sustainable access to high quality generic and biosimilar medicines for America’s patients. This is especially important as we recognize the 40th anniversary of the Hatch-Waxman Act. Since its passage in 1984, generics market share drastically increased patient access to medicines that may have previously been out of reach. Together with the AAM Board, its membership and staff, we will strengthen AAM’s efforts to impact the generic and biosimilar industries, and work to remove obstacles that impede patient access to generics and biosimilar medicines.”
Prior to her current role at Sandoz, Haruvi served as global head of M&A for Novartis after 14 years at Teva.
[Read more: Challenges continue, but generics companies see a bright future with biosimilars]
David Gaugh, interim president and CEO of AAM stated, “Keren has served AAM as vice chair and then as chair, fulfilling a vacancy in late 2023. Keren has demonstrated great leadership as a member representative for our association. We look forward to her continued leadership in the coming year as AAM continues its vital work to highlight the value and importance of generic and biosimilar medications to American patients and the overall healthcare ecosystem.”
[Read more: AAM report: Generic, biosimilar drugs generate $408B in savings]
AAM also elected Bob Hoffman, chief commercial officer of U.S. generics for Lupin as vice chair of the board, and Jeff Burd, president and CEO, North America of Ajanta Pharma USA as treasurer.